10.08.2013 Views

Télécharger le rapport (152 p.) - KCE

Télécharger le rapport (152 p.) - KCE

Télécharger le rapport (152 p.) - KCE

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>KCE</strong> reports vol. 19B Urgences 5<br />

3. MEASURES TO CHANGE EMERGENCY<br />

DEPARTMENT ATTENDANCE OF HOSPITALS:<br />

INSIGHTS FROM THE LITERATURE.<br />

3.1. BACKGROUND: THE ECONOMIC LOGIC OF CO-PAYMENTS IN<br />

HEALTH CARE<br />

In most developed countries with public health care systems patient cost-sharing b<br />

arrangements are imposed. Cost-sharing or user charges refer to a situation where the<br />

individual covered is required to pay part of the cost of care received 3, 2, 1 .<br />

Cost-sharing can take several forms on a continuum ranging from full thirdparty<br />

payment (zero cost-sharing) to full cost-sharing 4 . In this report we<br />

focus on direct forms of cost-sharing c (see Tab<strong>le</strong> 1), as the 12,5 € measure<br />

taken in Belgium for ED consultation falls into the category co-payment.<br />

Tab<strong>le</strong> 1. Direct forms of cost-sharing<br />

Form Definition<br />

co-payment the user pays a fixed fee (flat rate) per item or service<br />

co-insurance the user pays a fixed proportion of the total cost, the insurer<br />

pays the remaining proportion<br />

Deductib<strong>le</strong> the user pays a fixed quantity of the costs (up to a certain<br />

threshold), the insurer pays the remainder<br />

Source: based on WHO (HEN),2004 1 and Thomson, 2003 3<br />

Cost-sharing has different aspects to be considered and is still open for fundamental<br />

scientific and political debate: 1- efficiency aspects, related to fighting moral hazard; 2-<br />

the potential health effects and 3- equity effects.<br />

Cost-sharing can <strong>le</strong>ad to a reduction in overall utilisation of services and drugs, but does<br />

not necessarily <strong>le</strong>ad to a reduction in the overall costs of health care, because of<br />

possib<strong>le</strong> cost-shifting. Moreover, cost-sharing may inequitably affect vulnerab<strong>le</strong> groups<br />

(women, children and the poor). In order to improve the ÿ allocative efficiency it is<br />

considered important to have different cost-sharing requirements for different types of<br />

health interventions, and (from an equity point of view) to have different cost-sharing<br />

requirements for different peop<strong>le</strong> 5 .<br />

3.1.1. Efficiency argument: fighting moral hazard<br />

The basic economic argument for cost-sharing arrangements on health care markets is<br />

to avoid full health insurance patients to consume more health care than they would if<br />

they had to pay for the health services themselves. This type of prob<strong>le</strong>m is generally<br />

referred to as moral hazard . Cost-sharing may stimulate the cost consciousness of<br />

patients by restoring the price signal that was negated by insurance. Proponents of costsharing<br />

arrangements argue that direct payments at the point of use will discourage the<br />

use of services and hence reduce expenditures. The policy measure taken on ED<br />

attendance fits into this logic.<br />

b In this report we neg<strong>le</strong>ct other types of out-of-pocket payments such as informal and direct payments. Informal payments<br />

(envelope or under-the-tab<strong>le</strong> payments) are different payments to individual and institutional providers in kind or in cash<br />

outside official payment channels or for purchases meant to be covered by the health care system 1 . Direct payments are<br />

payments for goods and services that are not covered by any form of pre-payment or insurance and that are obtained from the<br />

private sector in pure private transactions 2, 1 .<br />

c Indirect cost-sharing refers to policies that can result in patient payments even though charges are not directly imposed.<br />

Coverage exclusions and certain forms of pharmaceutical regulatory mechanisms are some examp<strong>le</strong>s.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!